{
    "title": "104_s2051",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Pharmacotherapy Development Act of \n1996''.\n\n   TITLE I--DEVELOPMENT OF DRUGS FOR THE TREATMENT OF ADDICTIONS TO \n                             ILLEGAL DRUGS\n\nSEC. 101. RECOMMENDATION FOR INVESTIGATION OF DRUGS.\n\n    Section 525(a) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 360aa(a)) is amended--\n            (1) by striking ``States'' each place it appears and \n        inserting ``States, or for treatment of an addiction to illegal \n        drugs''; and\n            (2) by striking ``such disease or condition'' each place it \n        appears and inserting ``such disease, condition, or treatment \n        of such addiction''.\n\nSEC. 102. DESIGNATION OF DRUGS.\n\n    Section 526(a) of the Federal, Food, Drug, and Cosmetic Act (21 \nU.S.C. 360bb(a)) is amended--\n            (1) in paragraph (1)--\n                    (A) by inserting before the period in the first \n                sentence the following: ``or for treatment of an \n                addiction to illegal drugs'';\n                    (B) in the third sentence, by striking ``rare \n                disease or condition'' and inserting ``rare disease or \n                condition, or for treatment of an addiction to illegal \n                drugs,''; and\n                    (C) by striking ``such disease or condition'' each \n                place it appears and inserting ``such disease, \n                condition, or treatment of such addiction''; and\n            (2) in paragraph (2)--\n                    (A) by striking ``(2) For'' and inserting ``(2)(A) \n                For'';\n                    (B) by striking ``(A) affects'' and inserting ``(i) \n                affects'';\n                    (C) by striking ``(B) affects'' and inserting \n                ``(ii) affects''; and\n                    (D) by adding at the end thereof the following new \n                subparagraphs:\n    ``(B) The term `treatment of an addiction to illegal drugs' means \nany pharmacological agent or medication that--\n            ``(i) reduces the craving for an illegal drug for an \n        individual who--\n                    ``(I) habitually uses the illegal drug in a manner \n                that endangers the public health, safety, or welfare; \n                or\n                    ``(II) is so addicted to the use of the illegal \n                drug that the individual is not able to control the \n                addiction through the exercise of self-control;\n            ``(ii) blocks the behavioral and physiological effects of \n        an illegal drug for an individual described in clause (i);\n            ``(iii) safely serves as a replacement therapy for the \n        treatment of drug abuse for an individual described in clause \n        (i);\n            ``(iv) moderates or eliminates the process of withdrawal \n        for an individual described in clause (i);\n            ``(v) blocks or reverses the toxic effect of an illegal \n        drug on an individual described in clause (i); or\n            ``(vi) prevents, where possible, the initiation of drug \n        abuse in individuals at high risk.\n    ``(C) The term `illegal drug' means a controlled substance \nidentified under schedules I, II, III, IV, and V in section 202(c) of \nthe Controlled Substance Act (21 U.S.C. 812(c)).''.\n\nSEC. 103. PROTECTION FOR DRUGS.\n\n    Section 527 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n360cc) is amended--\n            (1) by striking ``rare disease or condition'' each place it \n        appears and inserting ``rare disease or condition or for \n        treatment of an addiction to illegal drugs'';\n            (2) by striking ``such disease or condition'' each place it \n        appears and inserting ``such disease, condition, or treatment \n        of the addiction''; and\n            (3) in subsection (b)(1), by striking ``the disease or \n        condition'' and inserting ``the disease, condition, or \n        addiction''.\n\nSEC. 104. OPEN PROTOCOLS FOR INVESTIGATIONS OF DRUGS.\n\n    Section 528 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n360dd) is amended--\n            (1) by striking ``rare disease or condition'' and inserting \n        ``rare disease or condition or for treatment of an addiction to \n        illegal drugs''; and\n            (2) by striking ``the disease or condition'' each place it \n        appears and inserting ``the disease, condition, or addiction''.\n\n TITLE II--DEVELOPMENT, MANUFACTURE, AND PROCUREMENT OF DRUGS FOR THE \n               ADDICTION OF COCAINE AND HEROIN ADDICTIONS\n\nSEC. 201. DEVELOPMENT, MANUFACTURE, AND PROCUREMENT OF DRUGS FOR THE \n              TREATMENT OF ADDICTIONS TO ILLEGAL DRUGS.\n\n    Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n351 et seq.) is amended by adding at the end thereof the following new \nsubchapter:\n\n        ``Subchapter D--Drugs for Cocaine and Heroin Addictions\n\n``SEC. 551. CRITERIA FOR AN ACCEPTABLE DRUG TREATMENT FOR COCAINE AND \n              HEROIN ADDICTIONS.\n\n    ``(a) In General.--Subject to the provisions of subsections (b) and \n(c), the Secretary shall, through the Institute of Medicine of the \nNational Academy of Sciences, establish criteria for an acceptable drug \nfor the treatment of an addiction to cocaine and for an acceptable drug \nfor the treatment of an addiction to heroin. The criteria shall be used \nby the Secretary in making a contract, or entering to a licensing \nagreement, under section 552.\n    ``(b) Requirements.--The criteria established under subsection (a) \nfor a drug shall include requirements--\n            ``(1) that the application to use the drug for the \n        treatment of addiction to cocaine or heroin was filed and \n        approved by the Secretary under this Act after the date of \n        enactment of this section;\n            ``(2) that a performance-based test on the drug--\n                    ``(A) has been conducted through the use of a \n                randomly selected test group that received the drug as \n                a treatment and a randomly selected control group that \n                received a placebo; and\n                    ``(B) has compared the long-term differences in the \n                addiction levels of control group participants and test \n                group participants;\n            ``(3) that the performance-based test conducted under \n        paragraph (2) demonstrates that the drug is effective through \n        evidence that--\n                    ``(A) a significant number of the participants in \n                the test who have an addiction to cocaine or heroin are \n                willing to take the drug for the addiction;\n                    ``(B) a significant number of the participants in \n                the test who have an addiction to cocaine or heroin and \n                who were provided the drug for the addiction during the \n                test are willing to continue taking the drug as long as \n                necessary for the treatment of the addiction; and\n                    ``(C) a significant number of the participants in \n                the test who were provided the drug for the period of \n                time required for the treatment of the addiction \n                refrained from the use of cocaine or heroin for a \n                period of 3 years after the date of the initial \n                administration of the drug on the participants; and\n            ``(4) that the drug shall have a reasonable cost of \n        production.\n    ``(c) Review and Publication of Criteria.--The criteria established \nunder subsection (a) shall, prior to the publication and application of \nsuch criteria, be submitted for review to the Committee on the \nJudiciary and the Committee on Economic and Educational Opportunities \nof the House of Representatives, and the Committee on the Judiciary and \nthe Committee on Labor and Human Resources of the Senate. Not later \nthan 90 days after notifying each of the committees, the Secretary \nshall publish the criteria in the Federal Register.\n\n``SEC. 552. PURCHASE OF PATENT RIGHTS FOR DRUG DEVELOPMENT.\n\n    ``(a) Application.--\n            ``(1) In general.--The patent owner of a drug to treat an \n        addiction to cocaine or heroin, may submit an application to \n        the Secretary--\n                    ``(A) to enter into a contract with the Secretary \n                to sell to the Secretary the patent rights of the owner \n                relating to the drug; or\n                    ``(B) in the case in which the drug is approved by \n                the Secretary for more than 1 indication, to enter into \n                an exclusive licensing agreement with the Secretary for \n                the manufacture and distribution of the drug to treat \n                an addiction to cocaine or heroin.\n            ``(2) Requirements.--An application described in paragraph \n        (1) shall be submitted at such time and in such manner, and \n        accompanied by such information, as the Secretary may require.\n    ``(b) Contract and Licensing Agreement.--\n            ``(1) Requirements.--The Secretary shall enter into a \n        contract or a licensing agreement with a patent owner who has \n        submitted an application in accordance with (a) if the drug \n        covered under the contract or licensing agreement meets the \n        criteria established by the Secretary under section 551(a).\n            ``(2) Special rule.--The Secretary shall enter into--\n                    ``(A) not more than 1 contract or exclusive \n                licensing agreement relating to a drug for the \n                treatment of an addiction to cocaine; and\n                    ``(B) not more than 1 contract or licensing \n                agreement relating to a drug for the treatment of an \n                addiction to heroin.\n        A contract or licensing agreement described in subparagraph (A) \n        or (B) shall cover not more than 1 drug.\n            ``(3) Purchase amount.--Subject to appropriations--\n                    ``(A) the amount to be paid to a patent owner who \n                has entered into a contract or licensing agreement \n                under this subsection relating to a drug to treat an \n                addiction to cocaine shall be $100,000,000; and\n                    ``(B) the amount to be paid to a patent owner who \n                has entered into a contract or licensing agreement \n                under this subsection relating to a drug to treat an \n                addiction to heroin shall be $50,000,000.\n    ``(c) Transfer of Rights Under Contracts and Licensing Agreement.--\n            ``(1) Contracts.--A contract under subsection (b)(1) to \n        purchase the patent rights relating to a drug to treat cocaine \n        or heroin addiction shall transfer to the Secretary--\n                    ``(A) the exclusive right to make, use, or sell the \n                patented drug within the United States for the term of \n                the patent;\n                    ``(B) any foreign patent rights held by the patent \n                owner;\n                    ``(C) any patent rights relating to the process of \n                manufacturing the drug; and\n                    ``(D) any trade secret or confidential business \n                information relating to the development of the drug, \n                process for manufacturing the drug, and therapeutic \n                effects of the drug.\n            ``(2) Licensing agreements.--A licensing agreement under \n        subsection (b)(1) to purchase an exclusive license relating to \n        manufacture and distribution of a drug to treat an addiction to \n        cocaine or heroin shall transfer to the Secretary--\n                    ``(A) the exclusive right to make, use, or sell the \n                patented drug for the purpose of treating an addiction \n                to cocaine or heroin within the United States for the \n                term of the patent;\n                    ``(B) the right to use any patented processes \n                relating to manufacturing the drug; and\n                    ``(C) any trade secret or confidential business \n                information relating to the development of the drug, \n                process for manufacturing the drug, and therapeutic \n                effects of the drug relating to use of the drug to \n                treat an addiction to cocaine or heroin.\n\n``SEC. 553. PLAN FOR MANUFACTURE AND DEVELOPMENT.\n\n    ``(a) In General.--Not later than 90 days after the date on which \nthe Secretary purchases the patent rights of a patent owner, or enters \ninto a licensing agreement with a patent owner, relating to a drug \nunder section 551, the Secretary shall develop a plan for the \nmanufacture and distribution of the drug.\n    ``(b) Plan Requirements.--The plan shall set forth--\n            ``(1) procedures for the Secretary to enter into licensing \n        agreements with private entities for the manufacture and the \n        distribution of the drug;\n            ``(2) procedures for making the drug available to nonprofit \n        entities and private entities to use in the treatment of a \n        cocaine or heroin addiction;\n            ``(3) a system to establish the sale price for the drug; \n        and\n            ``(4) policies and procedures with respect to the use of \n        Federal funds by State and local governments or nonprofit \n        entities to purchase the drug from the Secretary.\n    ``(c) Applicability of Procurement and Licensing Laws.--The \nprocurement and licensing laws of the United States shall be applicable \nto procurements and licenses covered under the plan described in \nsubsection (a).\n    ``(d) Review of Plan.--\n            ``(1) In general.--Upon completion of the plan under \n        subsection (a), the Secretary shall notify the Committee on the \n        Judiciary and the Committee on Economic and Educational \n        Opportunities of the House of Representatives, and the \n        Committee on the Judiciary and the Committee on Labor and Human \n        Resources of the Senate, of the development of the plan and \n        publish the plan in the Federal Register. The Secretary shall \n        provide an opportunity for public comment on the plan for a \n        period of not more than 30 days after the date of the \n        publication of the plan in the Federal Register.\n            ``(2) Final plan.--Not later than 60 days after the date of \n        the expiration of the comment period described in paragraph \n        (1), the Secretary shall publish in the Federal Register a \n        final plan. The implementation of the plan shall begin on the \n        date of the final publication of the plan.\n    ``(e) Construction.--The development, publication, or \nimplementation of the plan, or any other agency action with respect to \nthe plan, shall not be considered agency action subject to judicial \nreview.\n    ``(f) Regulations.--The Secretary may promulgate regulations to \ncarry out this section.\n\n``SEC. 554. AUTHORIZATION OF APPROPRIATIONS.\n\n    ``There are authorized to be appropriated to carry out this \nsubchapter, such sums as may be necessary in each of the fiscal years \n1997 through 1999.''."
}